# Geneweldes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneweldes

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Series A (Jul 16, 2025)
- Investors on record: 3

## About

Founded in 2022 and based in Hangzhou, China, Jiaweida (Hangzhou) Biotechnology Co,.Ltd, trading as Geneweldes, is a biotechnology company focused on building a high-standard synthetic biology platform for pharmaceutical applications. The company collaborates with pharmaceutical and industrial partners to develop efficient synthetic pathways for active pharmaceutical ingredients. In February 2026, Geneweldes raised a venture funding from Baiying Bio-industry Investment.
Geneweldes specializes in synthetic biology and recombinant protein expression, targeting high-value small molecule biologics including collagen, anti-aging proteins, anti-inflammatory proteins, and anti-oxidant peptides. The company has built a cell factory system for large-scale production and plans to launch two collagen-based functional products by 2025. Revenue is primarily generated from the commercial development and sale of small molecule recombinant protein products for medical, skincare, and health applications.

## Funding rounds

- Series A, Jul 16, 2025 — Changzhou Gaoxintou Venture, Huafang Capital, Changzhou Synthetic Biology Industry Research Institute Co., Ltd.

## Investors

- Changzhou Gaoxintou Venture (https://capitalatlas.ai/funds/changzhou-gaoxintou-venture) — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Changzhou Synthetic Biology Industry Research Institute Co., Ltd. — Series A